Introduction
CAS 441045-17-6 Eribulin Mesylate is a synthetic derivative of Halichondrin B, a substance isolated from a marine sponge. It is used in the treatment of metastatic breast cancer and liposarcomas. Eribulin Mesylate belongs to the class of drugs known as microtubule inhibitors and works by stopping the growth of cancer cells.
Chemical Properties
Eribulin Mesylate has the molecular formula C40H59NO11S and a molecular weight of 826.97 g/mol. It is a white to slightly yellow powder, soluble in water, dimethylsulfoxide, and methanol. The drug has a melting point of 208-215°C.
Pharmacokinetics
Eribulin Mesylate is administered intravenously and has a half-life of approximately 40 hours. The drug is metabolized by CYP3A4 and CYP3A5 enzymes in the liver, and the metabolites are excreted via the feces and urine.
Therapeutic Uses
Eribulin Mesylate is primarily used in the treatment of metastatic breast cancer and liposarcomas. It has been shown to improve overall survival in patients with advanced/metastatic breast cancer who have received previous chemotherapy. Eribulin Mesylate is also being studied for use in other types of cancer, including non-small cell lung cancer and bladder cancer.
Dosage and Administration
The recommended dose of Eribulin Mesylate for metastatic breast cancer is 1.4 mg/m2 intravenously on days 1 and 8 of a 21-day cycle. The drug is given until disease progression or unacceptable toxicity occurs.
Side Effects
The most common side effects of Eribulin Mesylate include fatigue, nausea, vomiting, constipation, fever, and headache. Other less common side effects include peripheral neuropathy, anemia, and neutropenia.
Contraindications and Precautions
Eribulin Mesylate is contraindicated in patients with a history of hypersensitivity to the drug or its components. The drug should be used with caution in patients with hepatic or renal impairment. Eribulin Mesylate may cause fetal harm and should not be used during pregnancy.
Drug Interactions
Eribulin Mesylate may interact with other drugs that are metabolized by the CYP3A4 and CYP3A5 enzymes. The drug may also decrease the effectiveness of hormonal contraceptives.
Overdose
In the event of an overdose, Eribulin Mesylate should be discontinued, and supportive measures should be taken to manage symptoms. There is no specific antidote for Eribulin Mesylate.
Conclusion
Eribulin Mesylate is an important drug in the treatment of metastatic breast cancer and liposarcomas. Its unique chemical structure and mechanism of action provide an effective treatment option for patients with these diseases.
Quote Inquiry
Contact us!
